---
title: "TScan CFO Jason A. Amello and CMO Chrystal Louis terminated; Gavin MacBeath assumes financial officer duties"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297777525.md"
description: "TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis due to strategic reorganization, effective September 2, 2026. Both departures are without cause, entitling them to severance packages including base salary and COBRA premiums. CEO Gavin MacBeath assumed the duties of Principal Financial and Accounting Officer on the same date."
datetime: "2026-09-02T11:23:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297777525.md)
  - [en](https://longbridge.com/en/news/297777525.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297777525.md)
generator: "portal-rs"
---

# TScan CFO Jason A. Amello and CMO Chrystal Louis terminated; Gavin MacBeath assumes financial officer duties

**TScan terminated CFO Jason A. Amello and CMO Chrystal Louis as part of a strategic reorganization, and CEO Gavin MacBeath assumed principal financial and accounting officer duties effective September 2, 2026.**

**Individual**

Jason A. Amello

Chrystal Louis, M.D., MPH

Gavin MacBeath, Ph.D.

**Role**

Chief Financial Officer

Chief Medical Officer

Chief Executive Officer; Principal Financial Officer and Principal Accounting Officer (assumed)

**Type of Change**

Terminated

Terminated

Assumed additional duties

**Effective Date**

September 2, 2026

September 2, 2026

September 2, 2026

**Reason**

Strategic Reorganization; constitutes Termination without Cause under employment agreement

Strategic Reorganization; constitutes Termination without Cause under employment agreement

Strategic Reorganization; to perform principal financial and accounting officer duties

**Replacement Info**

Not disclosed

Not disclosed

N/A

**Background Details**

Departure governed by Amello Employment Agreement dated Jan 29, 2024; subject to release, entitled to 12 months base salary and up to 12 months COBRA premiums

Departure governed by Louis Employment Agreement dated Apr 4, 2024; subject to release, entitled to 12 months base salary, any unpaid target bonus for FY2025, and up to 12 months COBRA premiums

Information regarding Dr. MacBeath is included in the company proxy filed Apr 17, 2026; no related-party or family relationships reported

**Board/Committee Role Changes**

Not disclosed

Not disclosed

Not disclosed

Original SEC Filing: TScan Therapeutics, Inc. \[ TCRX \] - 8-K - Sep. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TCRX.US](https://longbridge.com/en/quote/TCRX.US.md)

## Related News & Research

- [TScan Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard](https://longbridge.com/en/news/297777499.md)
- [TCRX: Focus shifts to in vivo TCR-T solid tumor therapies, with two candidates advancing to clinical studies](https://longbridge.com/en/news/297776068.md)
- [Jensen Huang Says AI CEOs May Have 'Ulterior', Maybe 'Political' Reasons For AI Doomsday Warnings: 'Go and Read Between The Lines'](https://longbridge.com/en/news/299637656.md)
- [HBM Healthcare Investments says Electra Therapeutics IPO raises USD 350 million](https://longbridge.com/en/news/299591426.md)
- [Micron Stock's (MU) AI Lead Is Expanding beyond HBM. I'm Bullish](https://longbridge.com/en/news/299626350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**